CONCERT PHARMACEUTICALS, INC. CNCE Income Statement

Concert pharmaceuticals, inc. (CNCE)

Income statement / TTM

Mar'20	Dec'19	Sep'19	Jun'19	Mar'19	Dec'18	Sep'18	Jun'18	Mar'18	Dec'17	Sep'17	Jun'17	Mar'17	Dec'16	Sep'16	Jun'16	Mar'16	Dec'15	Sep'15	Jun'15	Mar'15	Dec'14	Sep'14	Jun'14	Mar'14	Dec'13	Sep'13	Jun'13	Mar'13
Revenue:
License and research and development revenue
0	-	-	-	0	-	-	-	-	-	0	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
License and research and development revenue
-	-	-	-	-	-	-	-	-	-	-	-	138	-	458	2,141	5,324	6,574	7,579	8,288	6,269	6,576	6,679	4,942	21,148	23,408	0	0	0
Other revenue (Note 14 and Note 13)
-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	-	-	-	0	0	-	-	0	-	-	-	-	-	-
Milestone revenue
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	-	-	2,000	0	0	0
Total revenue
-	-	-	-	-	-	-	-	-	-	-	-	-	-	10,458	12,141	65,479	66,729	57,734	60,443	8,269	8,576	8,679	4,942	21,148	25,408	0	0	0
Operating expenses:
Research and development
58,012	59,816	58,397	55,917	50,283	43,149	36,114	32,219	30,642	30,223	31,318	32,236	34,767	36,983	34,709	33,790	32,394	28,885	29,567	31,001	28,824	27,474	25,736	22,835	22,345	21,790	0	0	0
General and administrative
19,339	20,276	20,805	22,383	22,919	22,940	22,648	21,203	21,396	21,019	19,348	17,913	16,034	14,358	14,101	13,929	13,400	13,056	12,787	12,976	12,395	11,700	10,375	9,047	8,602	8,028	0	0	0
Total operating expenses
77,351	80,092	79,202	78,300	73,202	66,089	58,762	53,422	52,038	51,242	50,666	50,149	50,801	51,341	48,810	47,719	45,794	41,941	42,354	43,977	41,219	39,174	36,111	31,882	30,947	29,818	0	0	0
Loss from operations
-77,272	-79,015	-78,125	-77,222	-72,171	-55,584	-48,258	100,915	102,312	92,649	93,234	-50,067	-50,663	-51,167	-38,352	-35,578	19,685	24,788	15,380	16,466	-32,950	-30,598	-27,432	-26,940	-9,799	-4,410	0	0	0
Investment income
2,683	2,987	3,258	3,237	3,014	2,787	2,597	2,344	1,839	1,336	851	513	490	447	382	307	201	124	94	72	62	49	39	27	14	21	0	0	0
Interest and other expense
-	-	-	-	-	-	-	-	-	-	0	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Interest and other expense
-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	0	-	-	-505	-686	-863	-1,150	-1,294	-1,069	-1,442	-1,667	0	0	0
Gain (Loss) on Extinguishment of Debt
-	-	-	-	-	-	-	-	-	-	0	-	-	-	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Unrealized loss on marketable equity securities
-2,240	-2,150	-3,658	-4,724	-3,929	-2,926	-1,359	-627	-1,296	0	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Income (Loss) before income taxes
-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	0	-	-	-	-	-	-	0	0	-	-	-	-	-
Loss before income taxes
-	-	0	0	-	-	0	0	-	-	0	0	-	-	-	-	-	-	0	0	-	-	-	-	-	-	-	-	-
Income Tax Expense (Benefit)
-	-	0	0	-	-	0	0	-	-	0	0	-	-	0	-	-	-	0	0	-	-	0	-	-	-	-	-	-
Net Income (Loss) Attributable to Parent
-76,817	-78,166	-78,528	-78,730	-73,387	-56,024	-41,241	104,211	104,509	95,639	90,349	0	0	-	0	-	19,296	24,174	14,563	15,285	-33,751	-31,699	-28,687	-27,982	-11,227	-6,056	0	0	0
Other comprehensive income:
Other comprehensive income:
Other Comprehensive Income (Loss), Securities, Available-for-Sale, Unrealized Holding Gain (Loss) Arising During Period, after Tax
532	106	206	332	442	270	-174	-284	-448	-400	-100	-87	-65	11	13	56	25	-4	5	-24	10	-18	8	11	-7	0	0	0	0
Comprehensive loss
-76,285	-78,060	-78,322	-78,398	-72,945	-55,754	-41,415	103,927	104,061	95,239	89,562	-49,846	-50,238	-50,709	0	0	0	-	0	0	0	-	0	0	0	-	-	-	-
Comprehensive income (loss)
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-6,056	0	0	0
Net (loss) income
-76,817	-78,166	-78,528	-78,730	-73,387	-56,024	-41,241	104,211	104,509	95,639	90,349	0	0	-	0	-	19,296	24,174	14,563	15,285	-33,751	-31,699	-28,687	-27,982	-11,227	-6,056	0	0	0
Accretion on redeemable convertible preferred stock
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	55	154	254	353	396	0	0	0
Undistributed earnings applicable to participating preferred shareholders
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	-
Net Income (Loss) Available to Common Stockholders, Basic
-	-	-	-	-	-	-	-	-	-	0	-	-	-	0	-	-	-	-	-	-	-	-	-	-	-6,452	0	0	0
Net Income (Loss) Available to Common Stockholders, Diluted
-	-	-	-	-	-	-	-	-	-	0	-	-	-	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Net loss per share applicable to common stockholders - basic and diluted (in dollars per share)
-0.70	-0.86	-0.72	-0.78	-0.93	-0.90	-0.74	-0.57	-0.19	-	-	-0.58	-0.60	-	-	-0.60	-0.63	-	-	-	-0.48	-	-	-	-0.76	-	-5.59	0.00	-1.46
Net (loss) income applicable to common stockholdersbasic and diluted
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	0	0	-	-	-	-
Earnings Per Share, Basic
-	-	-	-	-	-	-	-	-	-	5.61	-	-	-	-0.51	-	-	-	-0.39	1.89	-	-	-0.43	-0.45	-	-	-	-	-
Earnings Per Share, Diluted
-	-	-	-	-	-	-	-	-	-	5.44	-	-	-	-0.51	-	-	-	-0.39	1.80	-	-	-0.43	-0.45	-	-	-	-	-
Weighted-average number of common shares used in net loss per share applicable to common stockholders - basic and diluted (in shares)
29,110	23,855	23,807	23,790	23,508	23,434	23,421	23,402	23,223	-	-	22,579	22,377	-	-	22,217	22,198	-	-	-	18,726	-	-	-	9,188	-	1,293	-	1,290
Weighted Average Number of Shares Outstanding, Basic
-	-	-	-	-	-	-	-	-	-	22,694	-	-	-	22,229	-	-	-	21,949	21,762	-	-	18,098	17,937	-	-	-	1,290	-
Weighted Average Number of Shares Outstanding, Diluted
-	-	-	-	-	-	-	-	-	-	23,421	-	-	-	22,229	-	-	-	21,949	22,850	-	-	18,098	17,937	-	-	-	2,638	-
License and research and development revenue
Total revenue
-	-	1,077	1,078	-	10,505	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-